Wikisage, the free encyclopedia of the second generation, is digital heritage

Rufinamide: Difference between revisions

From Wikisage
Jump to navigation Jump to search
No edit summary
 
(5 intermediate revisions by the same user not shown)
Line 2: Line 2:
Otsuka et al. (2014) state rufinamide as an efficacious and well tolerated [[Antiepileptic drug|AED]]
Otsuka et al. (2014) state rufinamide as an efficacious and well tolerated [[Antiepileptic drug|AED]]
<ref>[http://www.epires-journal.com/article/S0920-1211(14)00228-9/pdf Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan]</ref>(cf. Alssad et Coren 2014) <ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256616/pdf/bcp0078-1264.pdf Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials] </ref>
<ref>[http://www.epires-journal.com/article/S0920-1211(14)00228-9/pdf Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan]</ref>(cf. Alssad et Coren 2014) <ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256616/pdf/bcp0078-1264.pdf Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials] </ref>
 
<gallery>File:Under construction icon.png</gallery>
 
<small>"Rufinamide received the status of orphan drug for [[epilepsy]] in 2004 in Europe"</small>
<small>"Rufinamide received the status of orphan drug for [[epilepsy]] in 2004 in Europe"</small>
<ref>[http://onlinelibrary.wiley.com/doi/10.1111/epi.12689/epdf  Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience]</ref>
<ref>[http://onlinelibrary.wiley.com/doi/10.1111/epi.12689/epdf  Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience]</ref>
<gallery>File:Rufinamid.svg.png</gallery>
 
It is an inductor of [[Cytochrome P450|CYP 450]]
==Weblinks==
==Weblinks==


Line 12: Line 12:


[http://www.pharmawiki.ch/wiki/index.php?wiki=Rufinamid Pharmawiki:Rufinamid]
[http://www.pharmawiki.ch/wiki/index.php?wiki=Rufinamid Pharmawiki:Rufinamid]
==ATC==
==[[ATC]]==
 
<gallery>File:Rufinamid.svg.png</gallery>
https://www.whocc.no/atc_ddd_index/?code=N03AF03
https://www.whocc.no/atc_ddd_index/?code=N03AF03


{{refs}}


<references/>
{{Wikidata|Q408565}}
{{Wikidata|Q408565}}


[[Category:Anticonvulsants]]
[[Category:Anticonvulsants]]

Latest revision as of 20:41, 20 March 2023

Lennox-Gastaut is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconclusive. Otsuka et al. (2014) state rufinamide as an efficacious and well tolerated AED [1](cf. Alssad et Coren 2014) [2]

"Rufinamide received the status of orphan drug for epilepsy in 2004 in Europe" [3]

It is an inductor of CYP 450

Weblinks

FLexikon:Rufinamid

Pharmawiki:Rufinamid

ATC

https://www.whocc.no/atc_ddd_index/?code=N03AF03

References

References:

Q408565 at Wikidata  Interwiki via Wikidata